Curcumin-loaded microemulsion: formulation, characterization, and in vitro skin penetration


Por: Luna-Canales, Irene Carolina, Delgado-Buenrostro, Norma Laura, Chirino Y.I., Nava-Arzaluz, Guadalupe, Piñón-Segundo E., Martinez-Cruz, Graciela, Ganem-Rondero, Adriana

Publicada: 1 mar 2023 Ahead of Print: 1 mar 2023
Resumen:
Objective: Formulation of curcumin in a microemulsion with a high loading capacity and that favors its penetration into the skin.SignificanceTake advantage of the properties of microemulsions to promote the penetration of curcumin into the skin, with the aim of enhancing its therapeutic effects. Methods: Curcumin was formulated in microemulsions based on oleic acid (oil phase), Tween((R)) 80 (surfactant), and Transcutol((R)) HP (cosurfactant). The microemulsion formation area was mapped by constructing pseudo-ternary diagrams for surfactant:co-surfactant ratios 1:1, 1:2, and 2:1. Microemulsions were characterized through measurements of specific weight, refractive index, conductivity, viscosity, droplet size, and in vitro skin permeation studies. Results: Nine microemulsions were prepared and characterized, showing clear, stable formulations with globule size dependent on the proportion of the components. The microemulsion with the highest loading capacity (60 mg/mL), based on Tween((R)) 80, Transcutol((R)) HP, oleic acid, and water (40:40:10:10) was able to penetrate the viable epidermis, finding a total amount of curcumin in the receptor medium at 24 h of 10.17 +/- 9.7 mu g/cm(2). The distribution of curcumin in the skin, visualized by confocal laser scanning microscopy, showed that the maximum amount was located between 20 and 30 mu m. Conclusion: The inclusion of curcumin in a microemulsion allows its passage into and through the skin. The localization of curcumin, especially in the viable epidermis, would be important for those cases where local conditions are sought to be treated.

Filiaciones:
Luna-Canales, Irene Carolina:
 Laboratorio de Investigación y Posgrado en Tecnología Farmacéutica (L-322, Campo 1), Universidad Nacional Autónoma de México, Cuautitlán Izcalli, Mexico

 Univ Nacl Autonoma Mexico, Lab Invest, Campo 1, Cuautitlan, Mexico

 Univ Nacl Autonoma Mexico, Posgrado Tecnol Farmaceut L 322, Campo 1, Cuautitlan, Mexico

Delgado-Buenrostro, Norma Laura:
 Laboratorio 10, Unidad de Biomedicina, Universidad Nacional Autónoma de México, Tlalnepantla, Mexico

 Univ Nacl Autonoma Mexico, Unidad Biomed, Lab 10, Tlalnepantla, Mexico

Chirino Y.I.:
 Laboratorio 10, Unidad de Biomedicina, Universidad Nacional Autónoma de México, Tlalnepantla, Mexico

Nava-Arzaluz, Guadalupe:
 Laboratorio de Investigación y Posgrado en Tecnología Farmacéutica (L-322, Campo 1), Universidad Nacional Autónoma de México, Cuautitlán Izcalli, Mexico

 Univ Nacl Autonoma Mexico, Lab Invest, Campo 1, Cuautitlan, Mexico

 Univ Nacl Autonoma Mexico, Posgrado Tecnol Farmaceut L 322, Campo 1, Cuautitlan, Mexico

Piñón-Segundo E.:
 Laboratorio de Sistemas Farmacéuticos de Liberación Modificada (L-13, UIM), Universidad Nacional Autónoma de México, Cuautitlán Izcalli, Mexico

Martinez-Cruz, Graciela:
 Laboratorio de Reometría, Nave 3000, Universidad Nacional Autónoma de México, Cuautitlán Izcalli, Mexico

 Univ Nacl Autonoma Mexico, Lab Reometria, Nave 3000, Cuautitlan, Mexico

Ganem-Rondero, Adriana:
 Laboratorio de Investigación y Posgrado en Tecnología Farmacéutica (L-322, Campo 1), Universidad Nacional Autónoma de México, Cuautitlán Izcalli, Mexico

 Univ Nacl Autonoma Mexico, Lab Invest, Campo 1, Cuautitlan, Mexico

 Univ Nacl Autonoma Mexico, Posgrado Tecnol Farmaceut L 322, Campo 1, Cuautitlan, Mexico

Univ Nacl Autonoma Mexico, Lab Sistemas Farmaceut Liberac Modificada L 13, UIM, Cuautitlan, Mexico
ISSN: 03639045





DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
Editorial
TAYLOR & FRANCIS LTD, 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND, Estados Unidos America
Tipo de documento: Article
Volumen: 49 Número: 1
Páginas: 42-51
WOS Id: 000943781400001
ID de PubMed: 36803628